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Human populations are endowed with a sophisticated genetic diversity of complement C4 and its flanking genes
RP, CYP21, and TNX in the RCCX modules of the major histocompatibility complex class III region. We applied
definitive techniques to elucidate (a) the complement C4 polymorphisms in gene sizes, gene numbers, and protein
isotypes and (b) their gene orders. Several intriguing features are unraveled, including (1) a trimodular RCCX
haplotype with three long C4 genes expressing C4A protein only, (2) two trimodular haplotypes with two long
(L) and one short (S) C4 genes organized in LSL configurations, (3) a quadrimodular haplotype with four C4 genes
organized in a SLSL configuration, and (4) another quadrimodular structure, with four long C4 genes (LLLL), that
has the human leukocyte antigen haplotype that is identical to ancestral haplotype 7.2 in the Japanese population.
Long-range PCR and PshAI-RFLP analyses conclusively revealed that the short genes from the LSL and SLSL
haplotypes are C4A. In four informative families, an astonishingly complex pattern of genetic diversity for RCCX
haplotypes with one, two, three and four C4 genes is demonstrated; each C4 gene may be long or short, encoding
a C4A or C4B protein. Such diversity may be related to different intrinsic strengths among humans to defend
against infections and susceptibilities to autoimmune diseases.
Introduction
Human populations are endowed with a distinct genetic
diversity of complement component C4 that may confer
varying intrinsic strengths on different individuals in the
defense against infections, but also may confer vulnera-
bilities for autoimmunity (Porter 1983; Blanchong et al.
2001; Martinez et al. 2001). Since 1969, when Rosenfeld
et al. (1969), using the antibody-antigen crossed electro-
phoresis, illustrated, for the first time, complement C4
polymorphisms in the hemolytic activities and electro-
phoretic mobilities, the progress toward understanding
the sophisticated genetics of human C4 has taken a some-
whatmeandering course. It appears that there aremultiple
allotypes of C4 proteins (Mauff et al. 1998). These protein
allotypes may be grouped into two classes: the acidic C4A
(MIM 120810), with lower hemolytic activities, and the
basic C4B (MIM 120820) with higher hemolytic activities
(Awdeh and Alper 1980). There is a wide spectrum of
C4A and C4B protein levels in the population—from
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complete absence of C4A or C4B, more C4A than C4B,
and more C4B than C4A to equal quantities of C4A and
C4B (Moulds et al. 1990; Rebmann et al. 1992). A single
locus with codominant expressions of the fast- and slow-
migrating forms of C4 was first proposed (Teisberg et al.
1976) but was soon replaced by a two-locus model with
one C4A gene and one C4B gene (O’Neill et al. 1978).
The differential levels of C4A and C4B proteins in the
plasma were explained by the presence of null or silent
alleles in either theC4A locus or theC4B locus. Themodel
was supported by work from independent laboratories
(Awdeh et al. 1979; Roos et al. 1982). However, there
are abundant exceptions to a rigid C4A-C4B, two-locus
model of C4 genes in the major histocompatibility com-
plex (MHC) class III region on chromosome 6 (Teisberg
et al. 1976; Carroll et al. 1984). Family segregation studies
showed considerable frequencies of single-locus haplo-
types encoding C4A or C4B proteins and of three-locus
haplotypes encoding one C4A and two different C4B al-
lotypes (Olaisen et al. 1980; Teisberg et al. 1988). There
is also mounting evidence for the homoexpression of C4A
proteins from two consecutive C4 loci (e.g., C4A3 A2)
(Raum et al. 1984; Rittner et al. 1984; Schendel et al.
1985). The phenomenon was observed because, in those
cases, each C4 gene encodes a polymorphic variant dis-
tinguishable in an allotyping gel (Awdeh and Alper 1980;
Sim and Cross 1986).
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Figure 1 The 1-2-3–locus concept of human C4 and RCCX modular variations. This map of the human MHC class III region shows
the physical length variants among the monomodular, bimodular, and trimodular RCCX structures. The MHC class I genes are located at the
telomeric end; the MHC class II genes are located at the centromeric end.
Molecular characterization of various C4A and C4B
genes from individuals with defined phenotypes allowed
identification of amino acid residues contributed to the
differential chemical reactivities of the activated C4A and
C4B, as well as their associated Rg and Ch blood-group
antigens (Carroll et al. 1984, 1990; Yu et al. 1986, 1988;
Dodds et al. 1996). It enabled the creation of molecular
biologic techniques to determine the presence and num-
ber of C4A and C4B genes in the MHC (Chung et al.
2002; Yu et al. 2002) and led to the elucidation of di-
chotomous features of C4 and other constituent genes of
the RP-C4-CYP21-TNX (RCCX) modules (fig. 1). First,
there are long and short forms of the C4 gene, 20.6 and
14.2 kb in size, respectively. The long C4 gene has an
endogenous retrovirus of 6.36 kb integrated into intron
9 (Dangel et al. 1994; Schneider et al. 2001). The size of
intron 9 in the short C4 gene is only 416 bp. Second, a
C4 gene may encode a C4A or C4B protein; the basis
for this variation is five nucleotide substitutions in exon
26, leading to four isotype-specific amino acid residues
(i.e., PCPVLD 1101-6 in C4A and LSPVIH 1101-6 in
C4B) (Belt et al. 1985; Yu et al. 1986). In haplotypes
with two or more C4 genes, duplication is discretely
modular of 32.7 kb (long [L]) or 26.3 kb (short [S])
including an intact C4A or C4B gene, a gene for the
steroid CYP21 (MIM201910) that is frequently the pseu-
dogeneCYP21A, and partially duplicated gene fragments
TNXA (MIM 600985) and RP2 (MIM 604977).
Initial structural characterization for a limited number
of clones revealed that theC4 gene that is linked to factor
B at the 5′ region (i.e., located at the telomeric end) is a
long gene encoding C4A; a short C4B gene is present at
the centromeric region linked to the functional CYP21B
gene (Carroll et al. 1984, 1985). However, population
studies using an informative or definitive RFLP analysis
coupled with phenotypic characterization of C4A and
C4B proteins revealed a great repertoire of length variants
for the RCCX modules with different combinations of
genotypic features for theRCCXconstituents (Blanchong
et al. 2000). A dynamic 1-2-3–locus model for C4 genes
is proposed as close to one-third of the chromosomes 6
in the normalwhite population that has eithermonomod-
ular RCCX haplotypes with a single copy of C4 gene or
trimodular haplotypes with three copies of C4 genes in
one chromosome. Only 55% of the white MHC hap-
lotypes have the two-locus structureswithC4A-C4B con-
figurations in the MHC. The remainder have different
combinations (or unequal numbers) of C4A and C4B
genes. It is speculated that the diversities in C4A and C4B
protein levels and in functional properties were one of
the intrinsic immune responses to defend against a vast
variety of bacterial, viral, and other microbial infections.
The high frequency of heterozygosity in RCCX length
variants is probably a mechanism to achieve or maintain
diversities of C4A and C4B proteins in the population,
since it would allow the exchange of genetic information
among homologs of the RCCX constituents. However,
heterozygous length variants of RCCX modules could
also promote unequal crossovers during meiosis, leading
to gene deletions, gene duplications, and disease associ-
Chung et al.: Complex Genetics of Human Complement C4 825
ations (Rupert et al. 1999; Z. Yang et al. 1999; Blanchong
et al. 2000, 2001; Jaatinen et al. 2002).
To define the dosage of C4A and C4B genes together
with the other RCCX constituents, we have applied
novel, more accurate techniques to directly address the
number of C4 genes present in a diploid genome and
in an MHC haplotype. Thus, we further demonstrate
the sophistications of C4A and C4B genetics. New va-
rieties of RCCX modular haplotypes are shown. These
include two trimodular structures with LSL configura-
tions, a trimodular LLL haplotype with homoexpres-
sion of C4A, and two quadrimodular haplotypes, each
with fourC4 genes, from pediatric patients with juvenile
rheumatoid arthritis (JRA) or with systemic lupus er-
ythematosus (SLE [MIM 152700]).
Material and Methods
Human Subjects, Genomic DNA, and Southern Blot
Analysis
Peripheral-blood samples were taken from healthy in-
dividuals, patients with SLE, and patients with pauciar-
ticular JRA and relatives after informed consent was
obtained, after approval by the Columbus Children’s
Hospital institutional review board. The isolation of ge-
nomic DNA and Southern blot analysis were performed
as described elsewhere (Blanchong et al. 2000; Chung
et al. 2002).
Labeled-Primer Single-Cycle Polymerization (LSP)–RFLP
Analysis of C4A and C4B
A 1.1-kb genomic fragment spanning complementC4
exons 26–29 was amplified by PCR and was subjected
to PshAI-LSP RFLP and XcmI-LSP RFLP, as described
elsewhere (Chung et al. 2002).
Human Leukocyte Antigen (HLA) Typing
HLA class I genes A, B, C, and class II genes DRB1,
DRB3/4/5, DPB1, and DQB1 were typed by sequence-
specific primer PCR of genomic DNA, using commercial
kits from One Lambda (for HLA A, B, and DR), Pel-
Freez (for HLA C), and INNO-LiPA (Innogenetics; for
HLA DQB1 and DPB1) and standardized protocols.
Complement C4 and C3
Polymorphisms of complement C4A and C4B proteins
were determined by immunofixation of EDTA-plasma
after published protocols (Yu et al. 2002). Complement
C3 typing was performed by immunofixation using a
method similar to that of C4, except that the quantity
of plasma was reduced by fivefold. Goat antiserum for
human C3 was purchased from Diasorin.
The concentrations of human C4 in EDTA-plasma
were determined by a sandwiched-ELISA method. All
dilutions were performed using PBS (pH 7.4). In brief,
diluted goat anti-human C4 sera (dilution, 1:300) in
PBS was coated on ELISA plate overnight at room
temperature. Washing with PBS and treatment with
blocking buffer (Pierce) were performed four times
after coating, reactions with diluted plasma, primary
antibody, and secondary antibody. Plasma samples at
1:4,000 dilution was added to each well and incu-
bated at room temperature for 1.5 h. The primary
antibody used was a rabbit antiserum against human
C4 (immunoglobulin G fraction; Sigma; 1:50 dilu-
tion). The secondary antibody used was a mouse mon-
oclonal against rabbit immunoglobulin G conjugated
with alkaline phosphatase (Sigma; 1:40,000 dilution).
After addition of the substrate PNPP (obtained from
Pierce) for 1 h, the reaction was terminated by addition
of 0.5 M NaOH, and optical density at 405 nm was
determined with an ELISA plate reader. A standardi-
zation curve of C4 protein levels was determined using
purified C4 protein (Calbiochem), with quantities vary-
ing from 1.56 ng to 100 ng and subjected to the same
experimental procedures in the same microtiter plate.
C4 protein level for each plasma sample was assayed
twice and each time in triplicate. The validity of
the assay was verified with a radial immunodiffusion
method using a kit purchased from the Binding Site.
Pulsed-Field Gel Electrophoresis (PFGE)
of PmeI- and PacI-Digested Genomic DNA
Genomic DNA in agarose plugs were digested with
PmeI or PacI restriction enzymes and processed as de-
scribed elsewhere (Chung et al. 2002; Yu et al. 2002).
The following conditions were optimized for PacI PFGE:
gradient, 6 V/cm; calibration factor, 1.4; initial switch
time, 1.79 s; final switch time, 12.91 s; run time, 37 h
40 min; included angle, 120; ramp, linear. The PmeI-
and PacI-PFGE gels were processed by Southern blot;
were hybridized with probes specific to C4d and to the
3′ region of TNX, respectively; and were subjected to
autoradiography.
Long-Range PCR of the Short C4 Genes
and PshAI-RFLP Analysis
Primers E9.5 and E31.3 were designed to anneal to
the 5′ end of exon 9 and to the 3′ end of exon 31 in C4,
respectively. The sequence for primer E9.5 is 5′-CCC
TGG AGA AGC TGA ATA TGG-3′ and E31.3 is 5′-CTT
CAG GGT TCC TTT GCT GT-3′. A 1# Premix D with
the Failsafe PCR Enzyme Mix (1.25 U) (Epicentre) was
used. PCR conditions were as follows: 1 cycle at 94C
for 3 min; 8 cycles at 94C for 45 s, 66C for 1 min
(decrease 0.5C/cycle), 72C for 9 min; 30 cycles at 94C
for 45 s, 60C for 1 min, 72C for 9 min; and 1 cycle
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at 72C for 15 min. For the RFLP analysis, one-fifth of
the PCR product was digested with PshAI (15 U) over-
night at 25C and was resolved by electrophoresis using
1% agarose gel.
Results
Homoexpression of C4A3 from a Trimodular RCCX
Haplotype with Three Long C4 Genes
Previous molecular genetic analysis revealed that
white female C008 has a total of sixC4 genes in a diploid
genome. PmeI-PFGE and TaqI-RFLP analyses showed
that C008 has the LLL/LLL structures for the RCCX
modules. In genomic PshAI or PshAI-PvuII Southern
blots hybridized to a C4d-specific probe, C008 exhibited
an unusual C4A:C4B ratio of 5:1 (Chung et al. 2002).
Together with C4-allotyping data, heterozygous C4A3
A3 A3/C4A3 A3 B1 haplotypes are predicted. The pres-
ence of three C4A genes on a chromosome (or haplo-
type) has never been reported. To confirm this obser-
vation, we recruited family members (two parents and
two children) of C008 for segregation analysis (fig. 2A).
Consistent results from the TaqI and PshAI RFLPs
and from the PmeI PFGE (figs. 2B–2D) indicate that the
parents, C8-1 and C8-2, each carry the heterozygous
LLL/LL RCCX structures and a total of five C4 genes.
The two children, C8-4 and C8-5, have the heterozygous
LLL/LS and LLL/S structures and a total of five and four
C4 genes, respectively. Interestingly, the ratio of C4A:
C4B as measured in the genomic PshAI-PvuII RFLP (fig.
2F), LSP-PshAI RFLP, and LSP-XcmI RFLP (fig. 2G) for
C8-1 was 4:1, whereas that for C8-2 was 3:2. There-
fore, it was deduced that C8-1 has haplotypes of C4A3
A3 A3/C4A3 B1, and that C8-2 has haplotypes of C4A3
A3 B1/C4A3 B1. This suggests that the C4A3 A3 A3
haplotype of C008 originates from C8-1. The dosage of
C4A and C4B were faithfully reflected in the corre-
sponding C4 allotypes (fig. 2E). By contrast, the ratio
of C4A:C4B as determined by the same techniques for
C8-4 and C8-5 were 3:2 and 3:1, respectively. There-
fore, it was deduced that C8-4 has haplotypes of C4A3
A3 B1/C4A3 B1 and that C8-5 has haplotypes of C4A3
A3 A3/C4AQ0 C4B1. In essence, the family segregation
study provides informative support for the presence of
homoexpression of C4A3 from a trimodular LLL struc-
ture that is present in all three generations: C8-1, C008,
and C8-5.
TaqI RFLP revealed that C8-1 has three CYP21B and
two CYP21A genes. On examination of the segregation
of CYP21B and CYP21A (fig. 2B, lane 1), it becomes
clear that the nontransmitted haplotype from C8-1 (i.e.,
bimodular LL) has the unusual configuration with 21B-
21B. It is of interest that, among the sixRCCXhaplotypes
present in the family of C008, there are six different com-
binations of C4A, C4B, CYP21A, and CYP21B genes.
Trimodular RCCX with Two Long and One Short C4
Genes
An RFLP analysis established that individual C007 has
heterozygous bimodular and trimodularRCCXstructures
with a total of four long and one short C4 genes in her
genome. These C4 genes could be organized as LLL/LS
or LLS/LL or LSL/LL. PmeI-PFGE analysis of C007 re-
vealed a 146-kb fragment corresponding to the bimodular
LL haplotype that is also shared by her two siblings, C7-
1 and C7-2 (figs. 3A and 3B, lanes 2 and 3). C007 also
has a 172-kb PmeI fragment corresponding to a trimodu-
lar structure with two long and one short C4 genes, im-
plying the presence of a novel trimodular RCCX structure
that may be either LLS or LSL.
Quadrimodular RCCX with Two Short and Two Long
C4 Genes in a Family with JRA
Case report.—J20 is a white female who developed
definite pauciarticular-onset JRA at 21 mo of age, when
she presented with left-knee synovitis. She has now been
followed for 10 years since the onset of her disease. Her
JRA has followed a polycyclic pauciarticular course. The
only joint that has ever been affected has been her left
knee. She has experienced three remissions and three
exacerbations of left-knee synovitis since her initial ep-
isode. She has been ANA positive but has never been
noted to have uveitis. Family history reveals a maternal
aunt with adult-onset rheumatoid arthritis.
Molecular genetic analysis.—The TaqI-RFLP analysis
of J20 shows the presence of the 7.0-, 6.4-, 6.0-, and
5.4-kb restriction fragments with respective relative
band intensities of 1:1:3:1, indicating the presence of
six C4 genes in total but a puzzled combination of long
and short C4 genes. PshAI-RFLP analysis for the relative
dosage of RP2 and RP1 revealed a 2:1 ratio with six
RCCXmodules on the two chromosomes (fig. 4B). PmeI
PFGE clearly shows that one of the chromosomes has
the bimodular LL and that the other chromosome has
a quadrimodular RCCX structure with two short C4
genes and two long C4 genes (fig. 4E). The configuration
of these four C4 genes is undetermined. Since the first
RCCX module (i.e., module I) on chromosome 6 always
starts with the RP1 that may be linked to a long C4
gene (characterized by a 7.0-kb TaqI fragment) or to a
shortC4 gene (characterized by a 6.4-kbTaqI fragment),
the quadrimodular RCCX chromosome in J20 starts
with RP1 linked to a short C4 gene because of the pres-
ence of the 6.4-kb TaqI fragment. Therefore, the con-
figuration of C4 genes in the quadrimodular structure
has one of the following three combinations: SSLL,
SLSL, or SLLS.
One of the parents of J20, J20-1, was recruited for
analysis. PmeI PFGE revealed that J20-1 and J20 have
identical patterns with the quadrimodular and bimodu-
lar haplotypes (data not shown). In TaqI RFLP, J20-1
Figure 2 Homoexpression of C4A in a trimodular LLL haplotype from a white family. A, Pedigree of the family C008. B, Genomic TaqI
RFLP, to show the RCCX modular variations. C, Genomic PshAI-RFLP, to show the number of RCCX modules by determining the relative
dosages of RP2 and RP1. D, PmeI-PFGE analysis, to show the length variants of RCCX haplotypes. E, Immunofixation, to show the relative
quantities of C4A and C4B allotypes. F, PshAI-PvuII RFLP, to show the relative dosage of C4A and C4B genes in each individual. G, LSP-
RFLP analysis, to determine the relative dosage of C4A and C4B. The dark-background panels are ethidium bromide–stained pictures that
contain artifact results because of heteroduplexes. The light-background pictures are results of autoradiography corresponding to LSP-RFLP
images free of heteroduplex effects.
828 Am. J. Hum. Genet. 71:823–837, 2002
Figure 3 A family with a trimodular RCCX haplotype consisting of two long and one short C4 genes. A, Genomic TaqI-RFLP analysis of
RCCX modules. B, PmeI-PFGE analysis, to show haplotypes of RCCX length variants. C, Immunofixation of EDTA-plasma, to show the qualitative
and quantitative variations of C4A and C4B proteins. D, Genomic PshAI-PvuII RFLP, to determine the relative dosage of C4A and C4B.
has the same 1:1:3:1 RP-C4 gene dosages (fig. 4A).
However, there are two notable differences. First, instead
of an equal ratio of CYP21A:CYP21B, as seen in J20,
a 2:1 ratio was observed in J20-1, suggesting that the
CYP21 haplotypes for J20 are 21A-21A-21A-21B/21B-
21B and that those for J20-1 are 21A-21A-21A-21B/
21A-21B. A PshAI-PvuII Southern blot analysis showed
that the ratio of C4A:C4B genes in J20 was 2:1 (or 4:
2) but showed an astounding 5:1 ratio in J20-1 (fig. 4D,
lane 1). Phenotyping experiments revealed the expression
of more C4A3 allotype than the C4B1 allotype in the
blood plasma of both individuals (fig. 4C). It is therefore
predicted that J20 has haplotypes C4A3 A3 A3 B1/A3
B1,whereas J20-1 has haplotypesC4A3 A3 A3 B1/C4A3
A3.
Quadrimodular RCCX with Four Long C4 Genes
in a Family with Pediatric Lupus
Case report.—CS-P4 is an Asian American female
who developed definite SLE at age 12 years. Six of the
11 American College of Rheumatology 1997 revised cri-
teria for classification of SLE were fulfilled (Tan et al.
1982; Hochberg 1997). The first manifestation of her
lupus was the development of multiple small-vessel vas-
culitic skin lesions on her fingers and toes (at distal dig-
ital tufts, along the sides of her fingers, and within pal-
mar flexor creases on the fingers). Shortly thereafter, she
developed a malar rash, polyarthritis, fatigue, a mouth
sore on her hard palate, and mild lymphadenopathy.
Initial laboratory testing revealed positive results for
the following: antinuclear antibody (1:1,280, speckled
pattern), anti-dsDNA antibody (1:40, Crithidia assay),
anti-Sm antibody (1:32), anti-RNP antibody (1:64), anti-
SS-A antibody (1:128), rheumatoid factor (1:320), anti-
Ribosomal P (130, with normal being !20), Coombs,
and lupus anticoagulant. Other abnormalities included
the following: low C3 (20, with normal being 185), low
C4 (!10, with normal being 115), thrombocytopenia
(107,000), anemia (10.8), low white-blood-cell counts
(3,000), and elevated erythrocyte-sedimentation rate (50,
Wintrobe). Her urinalysis results and renal function were
normal.
The patient has now been followed for 14 mo since
onset of symptoms. Her disease promptly came under
control and has remained under good control while she
was being treated, cumulatively with corticosteroid, hy-
droxychloroquine, and methotrexate. No additional lu-
pus features have developed, and she has remained free
of renal disease. At her last visit, her C3 and C4 were
normal (95 and 23 mg/dl, respectively). The patient’s
father is Chinese American. He is aware of no family
history of lupus or any other autoimmune disease. The
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Figure 4 A patient with JRA who had the quadrimodular RCCX haplotype consisting of two short C4 and two long C4 genes. A,
Genomic TaqI-RFLP analysis of RCCX modules. B, PshAI RFLP, to show the relative dosage of RP2 and RP1. C, Immunofixation, to determine
the C4A and C4B allotypes. D, Genomic PshAI-PvuII RFLP, to determine the relative gene dosage of C4A and C4B. E, PmeI PFGE, to show
the quadrimodular RCCX in J20 (lane 2). Lanes 1 and 3 are references for LLL/LL and LS/L RCCX structures, respectively.
patient’s mother is Japanese. She knows little of her
family history.
Molecular genetic analysis.—A TaqI-RFLP analysis of
the RCCX gene organizations in CS-P4 revealed a 2-0-
3-1 pattern for the restriction fragments corresponding to
RP1-C4L, RP1-C4S, RP2-C4L, and RP2-C4S, respec-
tively. The band intensity for CYP21B is half that of
CYP21A, as is the band intensity of TNXB to TNXA
(fig. 5A, lane 1). These data suggested the presence of six
C4 genes or RCCX modules in this patient, among them
four C4A and two C4B genes, as their corresponding
PshAI-PvuII restriction fragments have a ratio of 4:2 (fig.
5D). The blood sample was taken from the patient during
the lupus disease flare stage, when her C4A and C4B
proteins dropped to an almost undetectable level (fig. 5C,
lane 1), despite the presence of a considerable amount of
complement C3 (fig. 5C, anti-C3). A fresh blood sample
was taken 6 mo after her disease flare. The C4 allotyping
experiment showed the presence of C4A3, B1, and B2
(fig. 5C, anti-C4, lane 1A). A sandwich ELISA using goat
anti-human C4 as capture antibodies and rabbit anti-hu-
man C4 as primary antibodies confirmed a very low C4
concentration of 7.4 mg/dl during the relapse, and a par-
tial recovery to 19.7 mg/dl during remission.
Analyses of the RCCX modular structures of CS-P4
revealed a quadrimodular structure with four long C4
genes (LLLL) in one chromosome and a bimodular struc-
ture (LS) with two C4 genes in the other chromosome,
as suggested by the presence of the 210-kb and the 139-
kb PmeI fragments (fig. 5B, lane 1), respectively. A
PshAI-PvuII–RFLP analysis further suggested that CS-
P4 has four C4A and two C4B genes (fig. 5D, lane 1).
The quadrimodular LLLL structure is inherited from
the mother (CS-M4), who also has the 210-kb PmeI
fragment (fig. 5B, lane 2). Unexpectedly, CS-M4 has a
172-kb PmeI fragment corresponding to a trimodular
LLS or LSL, as in C007 (see the “Trimodular RCCX
with Two Long and One Short C4 Genes” subsection,
above). In other words, CS-M4 has a total of seven C4
genes or RCCX modules. Among them are probably five
C4A genes (encoding C4A3) and two C4B genes (en-
coding C4B1) (figs. 5C and 5D, lanes 2). The combined
data from TaqI-RFLP, PmeI-PFGE, PshAI-PvuII–RFLP,
and alloytping experiments showed that the patient’s
father, CS-F4, has the homozygous bimodular LS/LS
structures that encode C4A3 and C4B2.
Configurations of Long and Short C4 Genes
in Trimodular and Quadrimodular RCCX Haplotypes
It has been established that C007 and CS-M4 each
have a trimodular RCCX structure that is either LLS or
LSL, and J20 has a quadrimodular structure that may
be SSLL, SLSL, or SLLS. We further seek to resolve the
configuration of the RCCX structures by determining
whether a long or short C4 gene is located immediately
upstream from TNXB. Deliberate analyses of rare re-
striction sites in the centromeric end of the HLA class
III region (for accession numbers, see the Entrez Nucle-
otide Web site) revealed the presence of one PacI re-
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Figure 5 Quadrimodular and trimodular RCCX structures in an Asian family with a pediatric patient with SLE. A, Genomic TaqI-
RFLP analysis of RCCX modules. B, PmeI PFGE of the length variants in RCCX haplotypes. C, Immunofixation of human complement
C3 (anti-C3) and C4 (anti-C4). The sample from lane 1A was taken from the pediatric patient with SLE (CS-P4) while her disease was in
remission; the sample from lane 1 was taken from the patient in disease flare. Lanes 2 and 3 were samples from CS-M4 and CS-F4,
respectively. D, Genomic PshAI-PvuII RFLP, to determine the relative dosage of C4A and C4B.
striction site in TNXB, one site in the endogenous retro-
virus HERV-K(C4) in each long C4 gene, and none in
CYP21A/CYP21B and RP1/RP2. The next PacI restric-
tion site telomeric to RCCX is located at the intergenic
region between complement C2 and novel gene G10
(MHC Sequencing Consortium 1999; Milner and
Campbell 2001).
Figure 6 shows results of a PacI-PFGE analysis, per-
formed using a TNX probe for hybridization, of C007
and siblings, CS-P4 and parents, and J20. Lanes 1, 5,
and 7 respectively show that C007, CS-M4, and J20
each has a 58-kb restriction fragment representing the
presence of three linked C4 genes with a configuration
of LSL, a 48-kb restriction fragment representing a long
C4 gene linked to TNXB (C4L- TNXB), and a 32.7-kb
fragment corresponding to a long C4 gene linked to
another long C4 gene. In addition, J20 has a 110-kb
fragment corresponding to a PacI fragment spanning
from the intergenic region of G10 and C2 to RP1-C4S-
CYP21A-TNXA-RP2-C4L. From these observations, it
was deduced that C007 has a trimodular LSL and a
bimodular LL, that CS-M4 has the quadrimodular LLLL
and trimodular LSL (lane 5), and that J20 has the quadri-
modular SLSL and the bimodular LL (lane 7). The PacI
restriction patterns in C7-1 (lane 2), C7-2 (lane 3), CS-
P4 (lane 4), and CS-F4 (lane 4) are consistent with pre-
vious assignments of RCCX structures.
The Short Genes in LSL and SLSL Haplotypes Are C4A
Genes
Although C007 (LSL/LL) and CS-M4 (LLLL/LSL) have
C4 gene dosages of five and seven, respectively, there is
only one short C4 gene in each of their genomes. The
quadrimodular RCCX haplotype SLSL in J20 consists of
two short C4 genes, and the homologous chromosome
has bimodular LL. For determination ofwhether the short
C4 genes in the unusual RCCX structures are encoding
C4A or C4B proteins, specific genomic DNA fragments
containing the short intron 9—that is, without the en-
dogenous retrovirus HERV-K(C4)—and the C4A/C4B
isotypic sequences at exon 26 were amplified by PCR,
using the primer set E9.5 and E31.3 (fig. 6C). A 7.0-kb
genomic DNA fragment spanning exons 9–31 of the short
C4 gene was produced from each of these three individ-
uals (fig. 6D, lanes 2–4). A positive control from an in-
dividual with homozygous S/S that encodesC4B1 allotype
was included (fig. 6D, lane 1). Aliquots of these PCR
fragments were digested with PshAI (fig. 6D, lanes 5–8)
and were subjected to Southern blot analysis using a C4d
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Figure 6 Determining the configurations of long and short C4A and C4B genes in multi-modular RCCX structures. A, PacI-PFGE analysis
of long or short C4 genes linked to TNXA and TNXB. B, A scheme illustrating the locations (upward arrows) and size of the PacI restriction
fragments containing the C4 and TNX in three different length variants. C, Exon-intron structure of a short C4 gene and PCR strategy to
amplify the genomic region between exons 9 and 31. E9.5 and E31.3 are primers used for amplification of the 7.0-kb genomic fragment for
the short C4 gene. The PshAI restriction maps for the C4A and C4B genes are shown in red and blue, respectively. D, Restriction analysis of
the PCR fragments from four different individuals with short C4. Lanes 1–4 are undigested PCR products of E9.5-E31.3. Lanes 5–8 are digested
with PshAI. Lanes 1 and 5 are from an individual with homozygous, monomodular short C4B genes. E, Southern blot analysis of the genomic
fragments in panel D, using a C4d exons 22–25 probe.
probe that spans exons 22–25. In the amplified 7-kbDNA
fragment, there is a PshAI site, in exon 14, that is common
to the C4A and C4B genes, and there is an additional
site, in exon 26, that is specific to C4A (fig. 6C). The
probe hybridized to the 7-kb undigested PCR fragments
(fig. 6E, lanes 1–4), the 5.5-kb fragment characteristic of
C4B (fig. 6E, lane 5), and the 3.9-kb fragment specific to
C4A in C007, CS-M4, and J20 (fig. 6E, lanes 6–8). There-
fore, the short genes in LSL haplotypes of C007 and CS-
M4 and in SLSL haplotypes of J20 areC4A genes. Results
of C4-allotyping experiments indicated that these C4A
genes encode C4A3.
The HLA Haplotypes with the Unusual RCCX
Structures
The class I and class II alleles of the MHC (i.e., HLA)
in the four described families were determined and seg-
regated into haplotypes. The results are shown in table
1 and are categorized as follows:
Monomodular S RCCX.—The monomodular S struc-
ture with a single short C4B gene present in C8-5 is
typed as having HLA A*01 C*07 B*08, in the class I
region, and DRB1*03 DQB1*02 DPB1*0201, in the
class II region.
Homoexpression of CYP21B.—Two bimodular LL
structures are shown to have the infrequent CYP21B-
CYP21B configuration. The first is present in C8-1, with
HLA A*32 C*05 B*15(62) DRB1*04 DQB1*0301
DPB1*0401. The second is present in J20, with HLA
haplotype A*68 C*04 B*35 DRB1*13 DQB1*0603
DPB1*1901.
Homoexpression of C4A.—Bimodular LL structures
with homoexpression of C4A3 (i.e., C4A3 A3) is detected
in two haplotypes. The first is in C007 who has HLA
A*2 C*05 B*44 DRB1*13 DQB1*0603 DPB1*0401.
The second is present in J20-1 who has HLA haplotype
A*02 C*03 B*15(62) DRB1*13 DQB1*(0603 or 0607;
not determined) DPB1*0401. The trimodular LLL struc-
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Table 1
HLA Haplotypes in Families with Trimodular and Quadrimodular RCCX Structures
FAMILY, HAPLOTYPE,
AND MHC CLASS
LOCI
REMARKS1st 2nd 3rd 4th
Family C008:a
a:
I—HLA A*2 C*0303 B*15(62)
III—C4 A3 A3 A3 LLL
III—CYP 21A 21A 21B
II—HLA DRB1*13 DQB1*0603 DPB1*0401 DR52 group
b:
I—HLA A*32 C*05 B*15(62)
III—C4 A3 B1 LL
III—CYP 21B 21B
II—HLA DRB1*04 DQB1*0301 DPB1*0401 DR53 group
c:
I—HLA A*11 C*15 B*51
III—C4 A3 A3 B1 LLL
III—CYP 21A 21A 21B
II—HLA DRB1*01 DQB1*0501 DPB1*0501 DR1 group
d:
I—HLA A*03 C*07 B*07
III—C4 A3 B1 LL
III—CYP 21A 21B
II—HLA DRB1*15 DQB1*0602 DPB1*0401 DR51 group
e:
I—HLA A*31 C*08 B*65
III—C4 A3 B1 LS
III—CYP 21A 21B
II—HLA DRB1*07 DQB1*02 DPB1*0301 DR53 group
f:
I—HLA A*01 C*07 B*08
III—C4 B1 S
III—CYP 21B
II—HLA DRB1*03 DQB1*02 DPB1*0201 DR52 group
Family C007:b
a:
I—HLA A*2 C*05 B*44
III—C4 A3 A3 LL
III—CYP 21A 21B
II—HLA DRB1*13 DQB1*0603 DPB1*0401 DR52 group
bc
c:
I—HLA A*11 C*0303 B*55
III—C4 A3 A3 B1 LSL
III—CYP 21A 21A 21B
II—HLA DRB1*13 DQB1*0607 DPB1*0401 DR52 group
d:
I—HLA A*68 C*15 B*51
III—C4 A3 B1 LL
III—CYP 21A 21B
II—HLA DRB1*04 DQB1*0302 DPB1*0301 DR53 group
(continued)
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Table 1
HLA Haplotypes in Families with Trimodular and Quadrimodular RCCX Structures
FAMILY, HAPLOTYPE,
AND MHC CLASS
LOCI
REMARKS1st 2nd 3rd 4th
Family JRA 20:d
a:
I—HLA A*68 C*04 B*35
III—C4 A3 B1 LL
III—CYP 21B 21B
II—HLA DRB1*13 DQB1*0603 or
DQB1*0607e
DPB1*1901 DR52 group
bc
c:
I—HLA A*31 C*0303 B*15(62)
III—C4 A3 A3 A3 B1 SLSL
III—CYP 21A 21A 21A 21B
II—HLA DRB1*13 DQB1*0603 or
DQB1*0607e
DPB1*0401 DR52 group
d:
I—HLA A*02 C*03 B*15(62)
III—C4 A3 A3 LL
III—CYP 21A 21B
II—HLA DRB1*13 DQB1*0603 or
DQB1*0607e
DPB1*0401 DR52 group
Family CS4:f
a:
I—HLA A*11 C*01 B*46
III—C4 A3 B2 LS
III—CYP 21A 21B
II—HLA DRB1*09 DQB1*0303 DPB1*0501 DR53 group
b:
I—HLA A*11 C*0304 B*13
III—C4 A3 B2 LS
III—CYP 21A 21B
II—HLA DRB1*12 DQB1*0301 DPB1*1301 DR52 group
c:
I—HLA A*24 C*07 B*07
III—C4 A3 A3 A3 B1 LLLL
III—CYP 21A 21A 21A 21B
II—HLA DRB1*01 DQB1*0501 DPB1*0402 DR1 group
d:
I—HLA A*02 C*03 B*61
III—C4 A3 A3 B1 LSL
III—CYP 21A 21A 21B
II—HLA DRB1*11 DQB1*0301 DPB1*0201 DR52 group
a C8-1: a/b; C8-2: c/d; C008: a/c; C8-4: c/e; C8-5: a/f.
b C007: a/c; C7-1: a/d; C7-2: a/d.
c Not available.
d J20: a/c; J20-1: c/d.
e Not determined.
f CS-F4: a/b; CS-M4: c/d; CS-P4: a/c.
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Figure 7 Mechanistic models to generate LSL (A) and SLSL (B) modules of RCCX by unequal crossovers
ture with homoexpression of C4A3 in C008 is present
between HLA A*2 C*0303 B*15(62) and DRB1*13
DQB1*0603 DPB1*0401.
Trimodular structures expressing C4A3A3B1.—Three
haplotypes are shown that express two C4As and one
C4B. The first is present in a trimodular LLL of C008
and is located between HLA A*11 C*15 B*51 and
DRB1*01DQB1*0501DPB1*0501.The second is pres-
ent in C007, who has an LSL structure in HLA A*11
C*0303 B*55 andDRB1*13DQB1*0607DPB1*0401.
The third is in CS-M4, who also has an LSL structure,
but her HLA is A*02 C*0303 B*61 and DRB1*11
DQB1*0301 DPB1*0201.
Quadrimodular RCCX haplotypes.—The quadrimod-
ular LLLL in the pediatric patient with SLE CS-P4, en-
coding C4A3 A3 A3 B1, is present between HLA A*24
C*07 B*07 and DRB1*01 DQB1*0501 DPB1*0402.
The quadrimodular SLSL structure in J20, encoding
C4A3 A3 A3 B1, has HLA haplotype A*31 C*0303
B*15(62) DRB1*13 DQB1*0607 DPB1*0401.
Discussion
Studies on the molecular genetics of complement C4A
and complement C4B gene dosages and RCCX mod-
ular variations continue to yield surprises. Here, we
elucidated novel haplotypes with three and four RCCX
modules that contain long and short C4 genes. In an
unaffected white individual (C007) with HLA haplo-
type A*11 C*0303 B*55 DRB1*13 DQB1*0607
DPB1*0401 and in an unaffected Asian individual (CS-
M4) with HLA haplotype A*02 C*03 B*61 DRB1*11
DQB1*0301 DPB1*0201, trimodular RCCX haplo-
types with two long and one short C4 genes were dem-
onstrated by TaqI RFLP and PmeI PFGE. PacI PFGE
further shows that the configuration of the C4 genes
is LSL, with respect to RP1 at the telomeric end and
TNXB at the centromeric end. Long-range PCR am-
plification of the single short C4 genes in C007 and in
CS-M4 and the subsequent PshAI-RFLP analysis de-
finitively showed that the short gene (in the middle)
encodes C4A. Thus, the order of the three C4 genes in
each case is probably C4A3, A3, and B1.
By similar approaches, a peculiar quadrimodular
RCCX structure with two short and two long C4 genes
with a configuration of SLSL is elucidated in a white
pediatric patient with pauciarticulate JRA (J20). PshAI-
PvuII RFLP showed that three of these C4 genes encode
C4A and that the remaining gene encodes C4B. This
SLSL structure is located between HLA A*31 C*03
B*15(62) and DRB1*13 DQB1*0607 DPB1*0401. It
is noteworthy that the haplotype of the centromeric
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HLA class II alleles in this quadrimodular SLSL struc-
ture is identical to that of the trimodular LSL structure
in C007. A model to illustrate the generation of LSL
and SLSL is presented in figure 7. We suggest that the
trimodular LSL haplotype could have derived from an
unequal crossover between a bimodular LS and a bi-
modular LL (fig. 7A). Another unequal crossover be-
tween the trimodular LSL and a bimodular SS would
give rise to a quadrimodular SLSL and a monomodular
S (fig. 7B).
A different quadrimodular RCCX haplotype with
LLLL structure containing three C4A3 genes and one
C4B1 gene was detected in an Asian family with a pe-
diatric patient with SLE. The RCCX modules contain
an intact RP1 gene at one end and the intact CYP21B-
TNXB genes at the other end. HLA typing and a seg-
regation analysis showed that the LLLL structure is pres-
ent in the HLA haplotype A*24 C*07 B*07 DRB1*01
DQB1*0501 DPB1*0402. This is a relatively common
haplotype in the Japanese population, having a frequency
of 4.2% (Tokunaga et al. 1985). Tokunaga et al. (1991)
described it as ancestral haplotype (AH) 7.2. Their earlier
phenotypic and genotypic characterizations were in close
agreement with our observation: plasma proteins from
individuals with AH 7.2 had a substantially larger quan-
tity of C4A than of C4B; a TaqI-RFLP analysis of the
C4 genes yielded much higher intensities of the 6.0-kb
fragment corresponding to the RP2-C4L compared to
the 7.0-kb fragment corresponding to the RP1-C4L; and
PFGEofMluI-digested genomicDNA revealed a genomic
fragment ∼50 kb larger than that from individuals with
two C4 genes. Therefore, it was suggested—conserva-
tively, in retrospect—that three long C4 genes were pres-
ent in AH 7.2 (Tokunaga et al. 1991). The present study
definitively shows that AH 7.2 from the Asian patient
with SLE has four long C4 genes. In keeping with the
ethnicity of AH 7.2, the LLLL RCCX haplotype was
inherited from the patient’s mother, who immigrated to
the United States from Japan. Another HLA haplotype
with four repeating units of long C4 genes and CYP21A
pseudogenes was discovered in a patient with congenital
adrenal hyperplasia (CAH [MIM 201910]) who had
HLA haplotype A31 B51 DR4 (Collier et al. 1989).
Each of the two quadrimodular LLLL structures de-
scribed above could have been generated by an unequal
crossover between a trimodular LLL chromosome and
a bimodular LL chromosome. A crossover between LLL
and a regular bimodular LL partner with one CYP21A
gene and one CYP21B gene would give rise to the
LLLL(CYP21B) haplotype; a recombination between
LLL and a bimodular LL with two CYP21A genes
(which is a CAH-carrier haplotype) would generate the
LLLL(CYP21A) haplotype.
A third unexpected observation from the present
study is the homoexpression of C4A3 protein from a
trimodular RCCX structure with three long C4 genes
in a white female. This was unraveled through a com-
bination of precise genotyping experiments to determine
the total number and the relative dosage of C4A and
C4B genes, phenotyping experiments to detect the qual-
itative and quantitative variations of plasma C4A and
C4B levels, and family segregation studies. This may
not be the only case for the homoexpression of C4A
proteins from a trimodular LLL haplotype, since we
noticed a similar pattern in a published study of du-
plicated C4A genes in the French family St (Giles et al.
1987). On the basis of the genotyping data from TaqI-
RFLP analysis, phenotypic analysis of C4A and C4B
allotypes and a-chains of C4A and C4B proteins, and
hemolytic activities of the C4A and C4B proteins, it is
clear to us that the haplotype with HLA A24 B18 DR1
in the St family consists of an LLL structure that encodes
C4A3, A3, and A2, although the specific order of these
three C4 genes could not be deduced.
The phenomena described above reveal the plasticity
of the RCCX length variants, which leads to frequent
C4A and C4B gene-dosage variation in human popu-
lations. Just from the 13 members in four families, we
have demonstrated the magnitude of genetic diversities
in C4 and in RCCX. We observed the homoexpression
of C4A from bimodular LL (haplotype a,C007’s family;
haplotype d, J20’s family) and trimodular LLL (hap-
lotype a, C008’s family), the presence of LSL in a white
individual (haplotype c, C007’s family) and in Asian
American individuals (haplotype d,CS-P4’s family), and
the presence ofCYP21B-CYP21B in bimodular LL from
two different HLA haplotypes (haplotype a, J20’s fam-
ily; haplotype b, C008’s family). Although it is well
established that deficiency of CYP21B is the main cause
of CAH (White and Speiser 2000), it is not clearwhether
high dosage of CYP21B has any influence on the pro-
duction of corticols and sex steroids in an individual.
In other words, we have elucidated haplotypes consist-
ing of one, two, three, and four C4 genes, with different
combinations of long and short C4 genes encoding C4A
or C4B, and we have observed the variation in the dosage
of pseudogene CYP21A and functional gene CYP21B.
The C4A and C4B gene-dosage variation is a main con-
tributing factor for a wide range of C4A and C4B protein
levels in the circulation among different individuals. A
study of 125 white individuals has shown a significant
correlation betweenC4 gene dosages and serumC4 levels
and hemolytic activities (Y. Yang et al. 2001).
The sophistication in human complement C4 genetic
diversity demands special attention to data interpre-
tation when studying disease associations with C4A or
C4B deficiencies and protein polymorphisms. Of par-
ticular interest is the presence of six C4 genes in the
pediatric patient with lupus (CS-P4) and in the patient
with JRA (J20). It has been well documented that com-
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plete deficiency of C4A and C4B or deficiency of C4A
is an important risk factor of SLE (Rupert et al. 2002).
It is not clear, however, what role high C4 gene dosage
plays in the disease pathogenesis. One possibility is that
high C4 gene dosage could lead to the production of
larger quantities of C4 proteins at local tissues during
an inflammatory process that could exacerbate com-
plement-mediated tissue injuries.
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